Strattera 25mg Cap

Description

Strattera 25mg Cap

Strattera is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD.

In adults, the presence of symptoms of ADHD that were pre-existing in childhood should be confirmed. Third-party corroboration is desirable and Strattera should not be initiated when the verification of childhood ADHD symptoms is uncertain. Diagnosis cannot be made solely on the presence of one or more symptoms of ADHD. Based on clinical judgment, patients should have ADHD of at least moderate severity as indicated by at least moderate functional impairment in 2 or more settings (for example, social, academic, and/or occupational functioning), affecting several aspects of an individual’s life.

Additional information for the safe use of this product:

A comprehensive treatment programmed typically includes psychological, educational and social measures and is aimed at stabilizing patients with a behavioral syndrome characterized by symptoms which may include chronic history of short attention span, distractibility, emotional lability, impulsivity, moderate to severe hyperactivity, minor neurological signs and abnormal EEG. Learning may or may not be impaired.

Pharmacological treatment is not indicated in all patients with this syndrome and the decision to use the drug must be based on a very thorough assessment of the severity of the patient’s symptoms and impairment in relation to the patient’s age and the persistence of symptoms.

Similar Generic Drugs : Atomoxetine: Oral capsule (10mg) | Atomoxetine: Oral capsule (100mg) | Atomoxetine: Oral capsule (60mg) | Atomoxetine: Oral capsule (80mg) | Atomoxetine: Oral capsule (40mg) | Atomoxetine: Oral capsule (18mg) | Atomoxetine: Oral capsule (25mg)

Pharmaceutical particulars
1. List of excipients
Starch, pregelatinised (Maize)

Dimeticone

Capsule shell:

Sodium laurilsulfate

Gelatin

Capsule Shell Cap colourants:

10 mg: Titanium dioxide E 171

18 mg: Yellow iron oxide E172

25 mg, 40 mg, and 60 mg: FD&C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171

80 mg and 100 mg: Yellow iron oxide E172, Red iron oxide E172, Titanium dioxide E171

Capsule Shell Body colourants:

60 mg: Yellow iron oxide E172

10 mg, 18 mg, 25 mg and 80 mg: Titanium dioxide E 171

40 mg: FD&C Blue 2 (Indigo Carmine) E132 and Titanium dioxide E 171

100 mg: Yellow iron oxide E172, Red iron oxide E172, Titanium dioxide E171

Edible Black Ink SW-9008 (containing Shellac and Black Iron Oxide E172) or Edible Black Ink SW-9010(containing Shellac and Black Iron Oxide E172).

2. Incompatibilities
Not applicable.

3. Shelf life
3 years.

4. Special precautions for storage
This medicinal product does not require any special storage conditions.

5. Nature and contents of container
Polyvinyl chloride (PVC)/polyethylene (PE)/ Polychlorotrifluoroethylene, PCTFE blister sealed with aluminium foil lid.

Available in pack sizes of 7, 14, 28 and 56 capsules. Not all pack sizes may be marketed.

6. Special precautions for disposal and other handling
The capsules are not intended to be opened. Atomoxetine is an ocular irritant. In the event of capsules content coming in contact with the eye, the affected eye should be flushed immediately with water, and medical advice obtained. Hands and any potentially contaminated surfaces should be washed as soon as possible.